Lonza reported sales of 6.5 billion Swiss francs last year (about $8.5 billion in U.S. dollars) reflecting constant exchange rate (CER) sales growth of 21.7 percent, according to a release issued ...

XINTAI, SHANDONG, CHINA, January 19, 2026 /EINPresswire.com/ -- In recent years, the global pharmaceutical packaging ...

WuXi Biologics and Sinorda Biomedicine have jointly announced a strategic collaboration for the development and manufacturing of SND006.

Lonza Group stock is a top CDMO benefiting from biopharma outsourcing, strong growth, and expanding margins. Learn more about ...

Non-specific Endonuclease Market to reach US$ 726.6 Bn by 2036 at 6.5% CAGR, driven by rising biotechnology research, ...

The FDA AMT designation verifies NanoMosaic platform's ability to enhance efficiency, product quality, and scalability across AAV gene therapy manufacturing.

GLP-1 therapies are a cornerstone for the management of type 2 diabetes, supporting glycemic control and improving ...

Creative Diagnostics announces the release of a specialized portfolio of Antibiotic Residue Detection ELISA Kits. NEW ...

According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast projects the global active pharmaceutical ingredient market to expand from ...

INCHEON, South Korea, Jan. 28, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that it has received the ...

Discusses Zydus Collaboration, Global Manufacturing Expansion, and Patient Access Initiatives January 28, 2026 4:00 PM ...

Lonza has been a dominant player in contract development and manufacturing for decades. We think its outlook is bright, especially as drug manufacturing becomes more complex, with biologics and ...